Benitec Biopharma Inc.

NASDAQ:BNTC

Biotechnology

Healthcare
$8.27 +3.05%

+$0.36 today

Market cap
$288.53M
Beta
0.28
P/E (TTM)
-12.3
EPS (TTM)
-$0.99
52W Low $9.85High $16.76

Volume 0.13M

Average 0.11M

BNTC Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Benitec Biopharma Inc.NASDAQ: BNTC

Other Current Liabilities · Q3 FY2026 · quarter ended Mar 2026

Other current liabilities rises 27.0% from a year ago

Other current liabilities stood at $541K at the end of Q3 FY2026, up 27.0% from a year earlier and up 12.0% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.

Context

  • Other current liabilities amounted to 0.3% of total assets at the end of Q3 FY2026, down 0.1 pp from a year earlier.
  • Other current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether other current liabilities keeps rising in the next quarterly balance sheet after a +27.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$541K+12.0% QoQ
Last fiscal yearJun 2025
$426K-10.3% YoY
Year agoMar 2025
$426K+27.0% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.0%——
1 year-10.3%——
3-year CAGR+2.1%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
426K USD
Year-over-year change
-10.3%
4-year CAGR
+11.5%

Other Current Liabilities vs competitors

How BNTC compares with its peers on the latest reported figures

  • BNTC's Mar 2026 other current liabilities of $541K is the 9th highest of the 10 companies compared; the peer median is $8.9M.
  • Its year-over-year change of +27.0% is the 6th highest of 10, against a peer median of +71.0%.
  • Other current liabilities amounts to 0.3% of total assets for BNTC, versus a peer median of 4.0%.
BNTC Competitors Peer median
Other Current Liabilities for BNTC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AUTLAutolus Therapeutics plcMar 2026$39.96M +71.0%+74.1%7.6%
PRTCPureTech Health plcDec 2025$31.7M +16.6%+2.5%5.9%
SLDBSolid Biosciences Inc.Mar 2026$18.15M +122.3%+49.7%4.3%
XOMAXOMA Royalty Corp.Mar 2026$10.82M +2392.6%+61.4%4.0%
NGNENeurogene Inc.Mar 2026$8.9M +326.8%+235.8%3.4%
OCGNOcugen, Inc.Mar 2026$4.16M +12.8%+29.1%7.3%
QSIQuantum-Si incorporatedMar 2026$1.37M +698.3%—0.6%
GALTGalectin Therapeutics Inc.Mar 2026$545K -36.0%-49.3%3.5%
BNTCBenitec Biopharma Inc.Mar 2026$541K +27.0%+2.1%0.3%
LCTXLineage Cell Therapeutics, Inc.Mar 2026-$2.74M -231.8%-0.8%2.5%
Peer median (excluding BNTC) $8.9M+71.0%+39.4%4.0%

Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Cash & Equivalents19.77M4.06M2.48M50.87M97.74M
Short-term Investments00000
Net Receivables25K3K55K229K33K
Inventory00000
Other Current Assets15K14K13K579K741K
Total Current Assets20.61M4.82M3.73M51.67M98.52M
Property, Plant & Equipment (Net)577K993K613K449K991K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets194K160K122K87K83K
Total Non-current Assets771K1.15M735K536K1.07M
Total Assets21.38M5.97M4.46M52.21M99.59M
Account Payables274K422K1.14M1.35M201K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities276K400K472K475K426K
Total Current Liabilities1.37M2.53M3.98M4.92M1.8M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00038K0
Total Non-current Liabilities0559K284K38K495K
Total Liabilities1.37M3.09M4.26M4.96M2.3M
Common Stock1K001K2K
Retained Earnings(130.12M)(148.33M)(167.89M)(190.26M)(228.18M)
Accumulated OCI(1.46M)(1.25M)(830K)(892K)(839K)
Other Stockholders Equity00(0)00
Minority Interest00000
Total Equity20.01M2.88M202K47.25M97.3M
Total Debt213K811K559K284K849K
Net Debt(19.56M)(3.25M)(1.92M)(50.58M)(96.9M)

Benitec Biopharma Inc.

NASDAQ:BNTC

Intrinsic Alpha fair value

Locked

Current Price

$8.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.